|
Match
|
Document |
Document Title |
|
|
US20110182995 |
MEDICAL AND DENTAL BIOMATERIAL AND METHOD OF USE FOR THE SAME
The embodiments herein provide a dental and medical biomaterial and its use for sealing and/or filling the tooth and bone cavities. In the embodiments herein, the calcium salt, calcium oxide,... |
|
|
US20120282300 |
PROTEIN BIOMATERIALS AND BIOCOACERVATES AND METHODS OF MAKING AND USING THEREOF
The present invention relates to protein biocoacervates and biomaterials and the methods of making and using protein biocoacervates and biomaterials. More specifically the present invention... |
|
|
US20150252415 |
ARID1B AND NEUROBLASTOMA
Neuroblastomas are tumors of peripheral sympathetic neurons and are the most common solid tumor in children. We performed whole-genome sequencing (6 cases), exome sequencing (16 cases),... |
|
|
US20120282217 |
FOOT AND MOUTH DISEASE VIRUS (FMDV) CONSENSUS PROTEINS, CODING SEQUENCES THEREFOR AND VACCINES MADE THEREFROM
Provided herein is a nucleic acid comprising consensus amino acid sequence of foot-and-mouth disease FMDV VP1-4 coat proteins of FMDV subtypes A, Asia 1, C, O, SAT1, SAT2, and SAT3 as well as... |
|
|
US20110195103 |
COSMETIC OR DERMOPHARMACEUTICAL COMPOSITION CONTAINING PSEUDOALTEROMONAS FERMENT EXTRACT
Cosmetic or dermopharmaceutical compositions containing Pseudoalteromonas ferment extract for the treatment and/or care of the skin, scalp and/or nails, preferably to improve the barrier function... |
|
|
US20110097367 |
MONOLITHIC IN-SITU CROSS-LINKED ALGINATE IMPLANTS
A method of making and using a monolithic alginate implant is described. The implant is formed by providing an uncrosslinked, highly pure and high molecular weight alginate solution and injecting... |
|
|
US20120328561 |
METHOD FOR TREATMENT OF INFLAMMATORY GASTROINTESTINAL DISORDERS
Providing a new method of treating inflammatory gastrointestinal disorders and a food product for the prevention or improvement of inflammatory gastrointestinal disorders. Prevention or treatment... |
|
|
US20110038832 |
METHOD FOR TREATMENT OF MACULAR DEGENERATION USING (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE
Provided herein are methods of treating macular degeneration, which comprises administering to a patient in need thereof a therapeutically effective amount of... |
|
|
US20140234252 |
Composition and Methods for the Treatment of Degenerative Retinal Conditions
The present invention is directed to compositions and methods for the treatment of degenerative retinal conditions. According to a general aspect, the present invention is directed to inflammatory... |
|
|
US20140308239 |
CHIMERIC CYTOKINE FORMULATIONS FOR OCULAR DELIVERY
Featured herein are vehicle formulations and formulations containing a chimeric cytokine designed for e.g., ocular delivery. |
|
|
US20110206759 |
CCR7 LIGAND DELIVERY AND CO-DELIVERY IN IMMUNOTHERAPY
Chemokines may be administered to a patient for immunotolerization. Chemokines include CCL19 and CCL21. Materials and methods for accomplishing tolerization and described. |
|
|
US20140099270 |
Method of Use and Preparation of HSA Fusion Protein Composition for Skincare
The present invention provides a recombinant fusion protein which stimulates the rejuvenation and reactivation of skin and epidermal cells for improving skin appearance, smoothing wrinkles and... |
|
|
US20150218649 |
BIOMARKER ASSOCIATED WITH RISK OF MELANOMA REOCCURRENCE
The present invention provides a method of predicting the risk of reoccurrence of melanoma in a patient from whom melanoma tissue was previously removed which comprises the following: a. obtaining... |
|
|
US20140010781 |
SIRNA AGAINST CBL-B AND OPTIONALLY IL-2 AND IL-12 FOR USE IN THE TREATMENT OF CANCER
The invention relates to a method for the immune activation of NK cells by the reduction or inhibition of the Cbl-b function in said cells. This stimulates the congenital immune system and thus... |
|
|
US20120244115 |
TREATING NON-HEMATOPOIETIC CANCER WITH INTERLEUKIN 6
Use of IL-6 for treating non-hematopoietic cancers, e.g., gp130-negative cancers. Also disclosed is a method for identifying a cancer patient suitable for the IL-6 treatment. |
|
|
US20120009143 |
TREATING NON-HEMATOPOIETIC CANCER WITH INTERLEUKIN 6
Use of IL-6 for treating non-hematopoietic cancers, e.g., gp130-negative cancers. Also disclosed is a method for identifying a cancer patient suitable for the IL-6 treatment. |
|
|
US20140093476 |
METHODS FOR TREATING PAIN
Methods of treating pain by delivery of anti-inflammatory cytokines, proinflammatory cytokine antagonists, and agents that act to reduce or prevent proinflammatory cytokine actions, to the nervous... |
|
|
US20130045180 |
VACCINES, IMMUNOTHERAPEUTICS AND METHODS FOR USING THE SAME
Improved vaccines which include a nucleotide sequence that encodes immunomodulating protein operably linked to regulatory elements are disclosed. The improved vaccines include DNA vaccines,... |
|
|
US20120195852 |
VACCINES, IMMUNOTHERAPEUTICS AND METHODS FOR USING THE SAME
Improved vaccines which include a nucleotide sequence that encodes immunomodulating protein operably linked to regulatory elements are disclosed. The improved vaccines include DNA vaccines,... |
|
|
US20140314711 |
IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE
The invention relates to IL-22 polypeptides, IL-22 Fc fusion proteins and IL-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment... |
|
|
US20140142718 |
FLEXIBLE TISSUE MATRIX AND METHODS FOR JOINT REPAIR
A synthetic, flexible tissue matrix and methods for repairing hyaline cartilage defects in a joint using the flexible tissue matrix are described. The flexible tissue matrix includes a high... |
|
|
US20130129670 |
MACROPHAGE ACTIVATING FACTOR FOR USE IN THE TREATMENT OF CHRONIC FATIGUE SYNDROME (CFS) AND CFS-RELATED DISEASES AND DISORDERS
The present invention relates to Macrophage Activating Factors such as GcMAF and compositions thereof, for use in the treatment of a patient suffering from CFS/ME and/or XMRV infection. |
|
|
US20100310469 |
VACCINE IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS
A method of immunotherapy to treat cancer or a synergistic anti-cancer treatment by administering an effective amount of natural cytokine mixture (NCM), an effective amount of cyclophosphamide... |
|
|
US20140341843 |
PURIFIED PROTEINS
The present invention provides methods and compositions for the preparation and delivery of chimeric cytokine proteins, including cell cultures, methods of purification and purified compositions. |
|
|
US20150023908 |
SKIN CREAM
The present invention relates to skin care compositions, including cosmeceuticals, for topical application, and more particularly, a skin cream, comprising exosomes and cell culture medium... |
|
|
US20120100102 |
CANCER VACCINE
We disclose a vaccine comprising a pappalysin and vaccine compositions comprising a pappalysin. |
|
|
US20140186264 |
EXTRACELLULAR VESICLE-ASSOCIATED PROTEIN MARKERS OF CANCER
Extracellular vesicle-associated protein biomarkers for use in diagnosing and staging carcinomas, e.g., lung and ovarian cancers. |
|
|
US20150125384 |
MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINES
Modular nanoparticle vaccine compositions and methods of making and using the same have been developed. Modular nanoparticle vaccine compositions comprise an antigen encapsulated in a polymeric... |
|
|
US20110027221 |
Skincare Composition Comprising HSA Fusion Protein, Preparation Method And Uses Thereof
The present invention provides a recombinant fusion protein which stimulates the rejuvenation and reactivation of skin and epidermal cells for improving skin appearance, smoothing wrinkles and... |
|
|
US20130195794 |
CANCER VACCINE
The disclosure relates to a vaccine including at least one adjuvant useful in the prevention and treatment of blood cancers, for example lymphoma, leukaemia or myeloma. |
|
|
US20120225029 |
Skin Cream
The present invention relates to skin care compositions, including cosmeceuticals, for topical application, and more particularly, a skin cream, comprising cell culture medium conditioned by cells... |
|
|
US20140178331 |
METHOD OF TREATING CEREBRAL HEMORRHAGE AND SUBARACHNOID HEMORRHAGE COMPRISING ADMINISTERING METAL CHELATORS TO THE UPPER ONE-THIRD OF THE NASAL CAVITY
Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of cerebral hemorrhage and subarachnoid hemorrhage. Therapeutic agents are... |
|
|
US20110212136 |
Nanosphere/Microsphere Delivery System for the Treatment of Spinal Cord Injury
A formulation including injectable biodegradable nanospheres and/or microspheres as a delivery system for chondroitinase ABC (cABC) or a functional derivative of cABC to treat acute and chronic... |
|
|
US20140112884 |
COMPOSITION AND METHOD FOR TREATING CANCER
Pharmaceutical compositions useful as vaccines are described containing a purified surface or excreted protein qualitatively or quantitatively associated with a type of cancer, at least one... |
|
|
US20120282216 |
Composition and Method for Treating Cancer
Pharmaceutical compositions useful as vaccines are described containing a purified surface or excreted protein qualitatively or quantitatively associated with a type of cancer, at least one... |
|
|
US20140377221 |
BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION
The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present... |
|
|
US20140044676 |
USE OF TRUNCATED CYSTEINE IL28 AND IL29 MUTANTS TO TREAT CANCERS AND AUTOIMMUNE DISORDERS
Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or... |
|
|
US20120251488 |
USE OF TRUNCATED CYSTEINE IL28 AND IL29 MUTANTS TO TREAT CANCERS AND AUTOIMMUNE DISORDERS
Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or... |
|
|
US20110177024 |
USE OF TRUNCATED CYSTEINE IL28 AND IL29 MUTANTS TO TREAT CANCERS AND AUTOIMMUNE DISORDERS
Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or... |
|
|
US20130243723 |
VACCINE IMMUNOTHERAPY
A composition for treating cancer, including synergistic amounts of a primary cell-derived biologic having the cytokines IL-1, IL-2, IL-6, IL-8, TNF-α, and IFN-γ, and a cancer vaccine having at... |
|
|
US20120064035 |
VACCINE IMMUNOTHERAPY
A composition for treating cancer, including synergistic amounts of a primary cell-derived biologic having the cytokines IL-1, IL-2, IL-6, IL-8, TNF-α, and IFN-γ, and a cancer vaccine having at... |
|
|
US20120263794 |
TREATMENT OF EYE DISEASES USING ENCAPSULATED CELLS ENCODING AND SECRETING A NEUROPROTECTIVE FACTOR AND/OR AN ANTI-ANGIOGENIC FACTOR
The present application refers to cells, e.g. mesenchymal stem cells or mesenchymal stromal cells, or any further suitable cell, encoding and secreting a neuroprotective factor, an anti-angiogenic... |
|
|
US20130236418 |
Immunomodulatory Methods and Systems for Treatment and/or Prevention of Aneurysms
Immunomodulatory agents, T cell, compositions, methods and systems for treating and/or preventing an aneurysm and/or a condition associated thereto in an individual. |
|
|
US20140205647 |
METHOD FOR TREATING DEFECTIVE DURA MATER
Disclosed are an artificial dura mater and manufacturing method thereof. The artificial dura mater includes electrospun layers prepared by electrostatic spinning, at least one of which is a... |
|
|
US20150203919 |
METHODS FOR PREDICTING THE SURVIVAL TIME AND TREATMENT RESPONSIVENESS OF A PATIENT SUFFERING FROM A SOLID CANCER WITH A SIGNATURE OF AT LEAST 7 GENES
The present invention relates to a method for predicting the survival time of a patient suffering from a solid cancer comprising i) determining in a tumor sample obtained from the patient the gene... |
|
|
US20120164099 |
USE OF HUMAN PROSTATE CELL LINES IN CANCER TREATMENT
This invention is concerned with agents for the treatment of primary, metastatic and residual cancer in mammals (including humans) by inducing the immune system of the mammal or human afflicted... |
|
|
US20130295043 |
VACCINATION IN ELDERLY PATIENTS
The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at... |
|
|
US20150023912 |
COMBINATIONS OF ALBUMIN-BASED DRUG DELIVERY SYSTEMS
The present invention relates to a composition comprising at least two different albumin-based drug delivery systems, as well as to a pharmaceutical composition comprising said composition. |
|
|
US20140044673 |
Classifying Skin Lesions Using Mass Spectrometry Proteomic Approach
The present invention provides for a mass spectrometry proteomic approach to distinguishing Spitz nevi from Spitzoid malignant melanoma. Histology directed mass spectral profiling allows for... |
|
|
US20100310502 |
Method of treating local infections in mammals
An effective method is provided for local treatment against localized microbial infection, including abscesses, in skin and soft tissue and elsewhere in mammalian organs. The method employs... |